Listeria-based cancer vaccines that segregate immunogenicity from toxicity.
Ontology highlight
ABSTRACT: The facultative intracellular bacterium Listeria monocytogenes is being developed as a cancer vaccine platform because of its ability to induce potent innate and adaptive immunity. For successful clinical application, it is essential to develop a Listeria platform strain that is safe yet retains the potency of vaccines based on wild-type bacteria. Here, we report the development of a recombinant live-attenuated vaccine platform strain that retains the potency of the fully virulent pathogen, combined with a >1,000-fold reduction in toxicity, as compared with wild-type Listeria. By selectively deleting two virulence factors, ActA (DeltaactA) and Internalin B (DeltainlB), the immunopotency of Listeria was maintained and its toxicity was diminished in vivo, largely by blocking the direct inter
SUBMITTER: Brockstedt DG
PROVIDER: S-EPMC518841 | biostudies-literature | 2004 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA